[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB: A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol; 2007 Nov;107(2):177-85
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
  • PURPOSE: After initial surgery, there has been no established consensus regarding adjunctive therapy for patients with uterine carcinosarcoma (CS).
  • This study was designed to compare patient outcome following treatment with adjuvant whole abdominal irradiation (WAI) versus (vs.) chemotherapy for patients with this rare group of female pelvic malignancies.
  • PATIENTS AND METHODS: Eligible, consenting women with stage I-IV uterine CS, no more than 1 cm postsurgical residuum and/or no extra-abdominal spread had their treatments randomly assigned as either WAI or three cycles of cisplatin (C), ifosfamide (I), and mesna (M).
  • FIGO stage (both arms) was: I=64 (31%); II=26 (13%); III=92 (45%); IV=24 (12%).
  • Adjusting for stage and age, the recurrence rate was 21% lower for CIM patients than for WAI patients (relative hazard [RH]=0.789, 95% confidence interval [CI]: (0.530-1.176), p=0.245, 2-tail test).
  • CONCLUSION: We did not find a statistically significant advantage in recurrence rate or survival for adjuvant CIM over WAI in patients with uterine CS.
  • However, the observed differences favor the use of combination chemotherapy in future trials.

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):352-7 [11766739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):786-96 [14967435.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):204-8 [15047237.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):191-6 [15262141.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2127-30 [3793549.001]
  • [Cites] Stat Med. 1992 Apr;11(6):813-29 [1594819.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Gynecol Oncol. 1994 Jan;52(1):56-62 [8307502.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):493-8 [9190981.001]
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):8-13 [9454652.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(6):541-6 [10215437.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):232-7 [10021306.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):389-95 [10366465.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):630-4 [15721404.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):166-70 [15790453.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):295-300 [15923804.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):808-18 [18378136.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):147-53 [11063636.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):282-5 [11373106.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(3):194-200 [11501770.001]
  • [CommentIn] Gynecol Oncol. 2007 Nov;107(2):166-8 [17950382.001]
  • (PMID = 17822748.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517-15; United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA37517; United States / NCI NIH HHS / CA / U10 CA027469-19
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protective Agents; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ NIHMS33375; NLM/ PMC2752331
  •  go-up   go-down


2. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR: Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol; 2010 Jun 01;28(16):2727-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
  • PURPOSE: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor).
  • Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group.
  • Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas.
  • PATIENTS AND METHODS: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy.
  • Patients received paclitaxel at 175 mg/m(2) intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred.
  • Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy.
  • CONCLUSION: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Carboplatin / administration & dosage. Carboplatin / adverse effects. Confidence Intervals. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Immunohistochemistry. Infusions, Intravenous. Kaplan-Meier Estimate. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Probability. Prognosis. Program Evaluation. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):306-7 [9626805.001]
  • [Cites] Stat Med. 1998 Oct 30;17(20):2301-12 [9819829.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):177-85 [17822748.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):58-62 [17935761.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):147-53 [11063636.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):268-70 [11606082.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):311-4 [11972393.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):774-8 [15350372.001]
  • [Cites] Ann Intern Med. 1973 Oct;79(4):604-5 [4748282.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Am J Clin Oncol. 1985 Oct;8(5):350-2 [3840643.001]
  • [Cites] Biometrics. 1985 Sep;41(3):741-4 [4074823.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):271-4 [3948191.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):618-21 [3559652.001]
  • [Cites] Cancer Treat Rep. 1987 Jun;71(6):661-2 [3034423.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):935-8 [2914299.001]
  • [Cites] Am J Obstet Gynecol. 1989 Aug;161(2):309-12 [2548382.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):372-8 [2548936.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):32-4 [2154921.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 4):6-10 [2159188.001]
  • [Cites] Invest New Drugs. 1991 Feb;9(1):93-4 [2026490.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):400-2 [8677914.001]
  • (PMID = 20421537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2881851
  •  go-up   go-down


3. Nassar OA, Abdul Moaty SB, Khalil el-SA, El-Taher MM, El Najjar M: Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst; 2010 Jun;22(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.
  • PURPOSE: Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment.
  • This series investigated treatment options, relapse pattern, survival and prognostic factors.
  • PATIENTS AND METHODS: A total of 59 patients were treated in the National Cancer Institute, Cairo University, (2000-2007).
  • Leiomyosarcoma accounted for 42.2% followed by carcinosarcoma (35.5%) and endometrial stromal sarcoma (18.6%).
  • 40.7% had FIGO stage I disease, 30.5% were II, 16.9% were III and 11.9% were IV.
  • Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery.
  • Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.
  • Stage, adjuvant irradiation, tumor size, myometrial invasion, vascular and cervix invasion were significant factors in univariate analysis; nevertheless, multivariate prognostic factors were only stage (p=0.04) and adjuvant irradiation (p=0.01).
  • 5-year cumulative disease free survival for stage I was 63.6%, 41.2% for stage II, 10% for stage III and 0% in stage IV.
  • Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival.
  • Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy.
  • CONCLUSION: Diagnosis of uterine sarcoma is in itself a poor prognostic factor.
  • Complete cytoreductive surgery and adjuvant radiotherapy is essential for local control, provided tumor is limited to the uterus.
  • KEY WORDS: Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21860468.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


Advertisement
4. Ishiko O, Sumi T, Yasui T, Matsumoto Y, Kawamura N, Ogita S, Kamino T, Nakamura K, Yamada R: Balloon-occluded arterial infusion chemotherapy, simple total hysterectomy, and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervix. Oncol Rep; 2000 Jan-Feb;7(1):141-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balloon-occluded arterial infusion chemotherapy, simple total hysterectomy, and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervix.
  • We first performed 3 or 4 courses of balloon-occluded arterial infusion (BOAI) chemotherapy in 19 patients with advanced cancer of uterine cervix classified as stage III-IV according to the International Federation of Gynecology and Obstetrics.
  • In the patients in whom the first BOAI resulted in insufficient drug accumulation in tumor tissue, the ovarian arteries and veins were ligated to improve the therapeutic effect.
  • Ultimately simple total hysterectomy and radiotherapy were performed in 9 patients in whom the uterus was resectable (the combination group), and radiotherapy alone was conducted in the other 10 patients in whom hysterectomy was not practicable (the incomplete group).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Hysterectomy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10601608.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Aoki Y, Kase H, Watanabe M, Sato T, Kurata H, Tanaka K: Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol Oncol; 2001 Oct;83(1):1-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy.
  • OBJECTIVE: This study was performed to assess the prognostic factors and patterns of recurrence in stage III endometrial carcinoma treated with surgery and adjuvant chemotherapy.
  • METHODS: A retrospective review of 61 stage III endometrial carcinoma patients treated between 1988 and 1998 at Niigata University Hospital was performed.
  • All patients underwent surgery, followed by adjuvant chemotherapy consisting of intravenous cisplatin, doxorubicin, and cyclophosphamide.
  • The role of new adjuvant chemotherapy should be investigated to control distant failure in node-negative high-risk patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11585406.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Li J, Kong WM: [Prognostic factors of stage III endometrial carcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jan 20;89(3):198-200

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of stage III endometrial carcinoma].
  • OBJECTIVE: To investigate the prognostic factors of surgery-pathological stage III endometrial cancer.
  • METHOD: The clinical data of 102 patients with stage III endometrial cancer, aged 54.9 (27-79), 71 with endometrioid adenocarcinoma, 31 with non-endometrioid adenocarcinoma, 9 undergoing simple surgical treatment, and 42 receiving radiation, 16 receiving chemotherapy, and 35 receiving chemoradiation after surgery, were analyzed retrospectively.
  • RESULTS: Cox risk model analysis showed that the risk factors for the prognosis of stage III endometrial cancer were pathological types, method of treatment, vascular thrombosis, and age (all P < 0.05).
  • The average survival time of stage III a endometrial cancer patients purely positive in peritoneal cytology was 74.4 months, significantly longer than that of the patients with serosa and/or annex involvement (53.8 months, P < 0.05).
  • CONCLUSION: The independent prognostic factors of stage III endometrial cancer are pathological type, method of treatment, vascular thrombosis, and age.
  • The patients with, the prognosis of stage III a endometrial cancer simply positive in peritoneal cytology is better than that with serous and/or annex involvement.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537039.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


7. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ: Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus. Int J Gynecol Cancer; 2006 May-Jun;16(3):1364-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus.
  • The role of adjuvant therapy for malignant mixed müllerian tumors of the uterus has not been established.
  • Our aim was to review our experience with sequential adjuvant therapy using cisplatin and ifosfamide chemotherapy and radiotherapy after surgical staging.
  • The Cox proportional hazard regression model was used to assess the effect of treatment on survival after adjustment for age and stage.
  • Twenty-eight patients received adjuvant chemotherapy and 28 patients had adjuvant radiotherapy.
  • Twenty-one patients underwent sequential adjuvant chemotherapy and radiotherapy.
  • The 2- and 5-year survival for stage I and II diseases was both 95%, while the 2-year survival for stage III and IV diseases was 25%.
  • Patients who underwent sequential adjuvant therapy had an improved survival compared with patients who did not follow the protocol (P= 0.024).
  • Our results with sequential adjuvant therapy are encouraging and justify future randomized trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Ifosfamide / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / radiotherapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy / statistics & numerical data. Disease-Free Survival. Drug Evaluation. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Postoperative Period. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803531.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Yamamoto G, Shimada T, Nishida T, Ishida Y, Iba T, Nakata T, Ohtsuki T, Takigami K, Yamaguchi Y, Yoshitake K, Tanaka A, Tsuda Y: [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers]. Gan To Kagaku Ryoho; 2001 Aug;28(8):1111-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers].
  • Nedaplatin (cis-diammine-glycolato platinum: CDGP) is a platinum compound with a molecular weight of 303.18 that was recently developed in Japan.
  • There have been reports of the antineoplastic effects of Nedaplatin on cancers in the cranio-cervical region, lung, esophagus, urinary bladder, testis, ovary, and uterus.
  • In this study, we performed combined therapy of CDGP and fluorouracil (5-FU) for 8 patients with oral cancers, and evaluated the results to elucidate the clinical effect and adverse side effects.
  • The subjects were 8 patients with squamous cell carcinoma (5 males and 3 females aged 33-65 years).
  • The primary carcinoma regions were the tongue in 5 patients, oral floor in 2 patients, and mandibular gingiva in 1 patient.
  • The T-classification was T2 in 6 patients and T4 in 2 patients, and the clinical staging was Stage II in 5 patients, Stage III in 1 patient and Stage IV in 2 patients.
  • One patient was Grade IIA, 5 patients Grade IIB, and 2 patients Grade III.
  • Although the oral cancers in this study were extroverted superficial ulcerative cancers, and the number of patients was low at 8, this combined therapy is considered useful and worth evaluating in further accumulated cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Remission Induction

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Ivanov SI: [Modern tendencies in treatment of endometrial cancer stage III C]. Akush Ginekol (Sofiia); 2008;47(3):29-31
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern tendencies in treatment of endometrial cancer stage III C].
  • OBJECTIVE: The aim of our research work was to evaluate the potential of treatment in patients with endometrial cancer stage IIIC, with positive enlarged lymph nodes.
  • MATERIAL AND METHODS: 102 patients with endometrial cancer stage IIIC were researched for the period of 1990 till 2008.
  • In 30 patients--postoperative paraaortal radiotherapy, and 25 patients was applied postoperative chemotherapy.
  • In multivariation analysis, the independent prognostic factors were: the size of the lymph node, the residual tumour/metastatic lymph nodes/--p < 0,001, the age < 65 years--p = 0,001, and the implementation of adjuvant chemotherapy/p = 0,016/.
  • CONCLUSIONS: In patients with endometrial cancer stage IIIC, the resection/debulking/ of macroscopic enlarged lymph nodes and the implementation of adjuvant chemotherapy in addition to radiotherapy is connected with better survival rate.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756829.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


10. Gocheva L, Slavchev B: Whole abdominal irradiation in endometrial cancer - a single institution study. J BUON; 2009 Oct-Dec;14(4):613-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole abdominal irradiation in endometrial cancer - a single institution study.
  • PURPOSE: To examine the use of whole abdominal irradiation (WAI) open field technique in patients with stage III endometrial cancer (EC).
  • METHODS: Between 1993 and 2007, 26 patients (age 39-70 years, median 58) with stage III EC (IIIA 15, IIIB 2, IIIC 8) were treated with WAI after primary surgery.
  • In 84% of the patients WAI consisted of 30 Gy, delivered mainly in daily fractions of 1.5 Gy (81%), 5 fractions per week.
  • For the remaining patients the dose was 25 Gy (8%) and 20 Gy (8%), respectively.
  • After abdominal RT, 85% of the patients were given a pelvic boost to reach 45 - 50 Gy with 1.8 Gy/fraction/day, using a Co 60 unit.
  • In 5 (19%) patients boost to 45-50 Gy with 1.8 Gy/fraction/day to other risk sites was also given.
  • Two (8%) of 26 patients received 2 cycles of platinum-based chemotherapy.
  • The mean follow-up time was 13.41 years.
  • RESULTS: The treatment time ranged from 14-74 days, median 48.
  • Ten (38.5%) patients received their treatment with no interruption, and in 16 (61.5%) patients RT was transiently interrupted because of acute gastrointestinal and hematological toxicity.
  • Neither grade 4 acute complications nor mortality while receiving treatment were observed.
  • Late side effects (grade 2 gastrointestinal complications) developed in 1 (5%) patient.
  • CONCLUSION: WAI achieves a quite favorable 5- and 14-year survival rate with an acceptable risk of acute and late side effects in properly selected patients with stage III EC.
  • WAI as a sole or a part of combined treatment warrants further investigation in patients with high-risk EC.
  • [MeSH-major] Abdomen / radiation effects. Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148451.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Macchia G, Ferrandina G, Legge F, Deodato F, Ruggieri V, Lorusso D, Padula GD, Valentini V, Cellini N, Scambia G, Morganti AG: Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase II study (ESTER-1). Am J Clin Oncol; 2010 Dec;33(6):577-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase II study (ESTER-1).
  • INTRODUCTION: The aim of this phase II study was to evaluate response and toxicity of a prolonged chemoradiation regimen in patients with locally advanced cervical cancer.
  • PATIENTS AND METHODS: Three cycles of concomitant chemotherapy were used with cisplatin (20 mg/m², 2-hour intravenous infusion, days 1-4) and 5-fluorouracil (1000 mg/m², 24-hour continuous intravenous infusion, days 1-4) administered at weeks 1, 5, and 9 of radiotherapy.
  • The CTV was defined as follows: gross tumor volume, upper half of the vagina (if not involved) or the whole vagina (if clinically involved), uterus, obturator nodes, external iliac nodes, internal iliac nodes, and the presacral nodes (cranial to S2).
  • The prescribed dose to the PTV was 50 Gy, 2 Gy/fraction (ICRU 62) delivered in 25 fractions with a 2-week break at 20Gy and 40 Gy (split-course technique).
  • Clinical stage was: IB2-II: 19 patients (76%), III-IVA: 6 patients (24%).
  • All patients completed the prescribed dose of chemoradiation and were evaluated 4 weeks after the end of treatment.
  • About 32% of patients experienced grade 3 to 4 toxicity, in particular, grade 3 or 4 hematological toxicity was observed in 7 patients and 1 patient developed grade 3 genitourinary toxicity.
  • No patients developed grade 3 gastrointestinal toxicity or skin toxicity.
  • Seven patients (28%) showed a complete response (CR) to treatment, and 7 patients (28%) showed microscopic residual disease (μPR), totaling 14 patients (56%) complete/partial microscopic responses.
  • Perioperative morbidity was higher than reported in historical controls especially in terms of tissue fibrosis (64%) and perioperative urinary toxicity (14%).
  • CONCLUSION: A prolonged treatment with more chemotherapy courses does not improve tumor response and increases the risk of perioperative complication.
  • This treatment regimen, considering the low incidence of acute gastrointestinal toxicity, might be tested in the adjuvant setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Kaplan-Meier Estimate. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Preoperative Care. Prospective Studies. Radiotherapy Dosage. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023568.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Stevens M, Rey A, Bouvet N, Ellershaw C, Sanchez de Toledo J, Oberlin O: SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS). J Clin Oncol; 2004 Jul 15;22(14_suppl):8515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS).
  • Principal study objectives were: low and standard risk patients, to maintain excellent survival with limited chemotherapy and very selective use of local therapy.
  • ; high risk patients, to explore survival advantage for an intensified chemotherapy strategy in a randomised trial.
  • METHODS: Eligibility for randomisation included age ≥ 6 months ≤18 years, no distant metastases, diagnosis within previous 8 weeks without prior treatment except surgery, pathology available for central review, written consent according to institutional requirement.
  • From July 1995 to July 2003, 456 high risk patients (incompletely resected embryonal RMS, undifferentiated sarcoma and soft tissue PNET at all sites except paratesticular, vagina and uterus, and all alveolar RMS) were randomised to receive IVA (ifosfamide, vincristine, actinomycin D) or a 6 drug combination (IVA + carboplatin, epirubicin, etoposide) both delivered over 27 weeks.
  • Cumulative dose / m<sup>2</sup> = ifosfamide 54g (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug).
  • Delivery of radiotherapy was determined according to site and / or response to chemotherapy ± surgery.
  • Non randomised exceptions were: orbital tumours (allocated IVA); SIOP stage III (node positive) and young (age < 3yr) parameningeal tumours (allocated 6 drugs).
  • RESULTS: Data given only for randomised patients [Figure: see text] Toxicity was significantly greater (infection, myelosuppression, mucositis) for the 6 drug arm.
  • CONCLUSIONS: Intensification of chemotherapy provides no overall advantage for non metastatic RMS / other chemosensitive STS, and adds toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013776.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Fujiwara K, Ohashi Y, Nakayama H, Nishimura R, Shimizu K, Mitsuhashi N, Hatae M, Ochiai K, Hatano K, Noda K: Phase III double-blind randomized trial of radiation therapy for stage IIIB cervical cancer in combination with low or high dose Z-100, immunomodulator widely used in Japan. J Clin Oncol; 2004 Jul 15;22(14_suppl):5029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III double-blind randomized trial of radiation therapy for stage IIIB cervical cancer in combination with low or high dose Z-100, immunomodulator widely used in Japan.
  • : 5029 Background: The Specific Substance of Maruyama (SSM) is a well-known immunomodulator that has been used in Japan as an unapproved drug in the treatment of over 240,000 cancer-bearing patients since 1970.
  • The aim of this study is to investigate whether Z-100 enhances the efficacy of radiation therapy (RT) for locally advanced cervical cancer of the uterus.
  • METHODS: Between 1995 and 1999, 221 (217 evaluable) patients with stage IIIb squamous cell carcinoma of the uterine cervix were randomly assigned to treatment with either 0.2 μg Z-100 (Group L: n=109) or 40 μg Z-100 (Group H: n=108) in a double-blind manner in combination with conventional RT.
  • CONCLUSIONS: It was suggested that RT combined with the immunomodulator Z-100 improved the survival of patients with locally advanced cervical cancer.
  • A randomized placebo controlled trial is under planning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015511.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Amin C, Hemphill B, Sittisomwong T, Malpica A, Hunt W, Verschraegen C: Characteristics of patients with endometrial stromal sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with endometrial stromal sarcoma.
  • : 5145 Background: Endometrial stromal sarcoma (ESS) is by definition a low grade sarcoma, accounting for less than 1% of all tumor malignancies.
  • By comparison, the prevalence of endometrial cancer is 700 per million women.
  • Because of its rarity, the natural history of the disease and the optimal therapy have not been well established.
  • METHODS: After IRB approval, the charts of 78 patients diagnosed for the first time with ESS and treated at the University of Texas MDACC were reviewed, with emphasis on patient demographics, therapies, recurrence, and survival.
  • Endometrial FIGO stage was I in 52%, II in 6%, III in 30%, and IV in 12%.
  • The primary site was uterus in 87% and extra-uterine in 13%.
  • The median age of onset is younger than the one of endometrial cancer, but interestingly about 75% are postmenopausal at diagnosis.
  • Various treatments including hormonal therapy, chemotherapy, radiation therapy, and hysterectomy with oophorectomy have been used, and we plan to study their impact on this disease, to present at the annual meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016810.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Silva EG, Deavers MT, Bodurka DC, Malpica A: Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol; 2004 Feb;28(2):244-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa.
  • In this study, we investigated HMB-45 expression in epithelioid uterine leiomyosarcomas with clear cell areas.
  • Presenting symptoms were uterine bleeding (three), abdominal pain (one), and a pelvic mass (one).
  • One patient had stage II disease, one stage III, and three stage IV.
  • Two received radiotherapy, and three were also treated with chemotherapy.
  • Three patients died of disease at 9, 30, and 32 months; one patient is alive with progressive disease at 6 months, and one patient (stage II disease) is alive with no evidence of disease at 8 months.
  • Unequivocal uterine epithelioid leiomyosarcomas may have clear cells positive for HMB-45.
  • These tumors might belong to the group of lesion designated as PEComas; however, it is advisable to designate them as uterine leiomyosarcomas.
  • In uterine smooth muscle tumors, some epithelioid cells most likely undergo clear cell changes and become positive for HMB-45.
  • It would be advisable to perform this stain in all epithelioid smooth muscle tumors of the uterus.
  • [MeSH-major] Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Neoplasm Proteins / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15043315.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


16. Li YF, Li MD, Wu QL, Liu FY, Li JD, Zou JL, Huang YW: [Clinical analysis of 57 patients with ovarian dysgerminoma]. Ai Zheng; 2002 Jan;21(1):79-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The data of 57 patients with pure Ovarian Dysgerminoma were analyzed retrospectively, who were admitted to Cancer Center, Sun Yat-sen University of Medical Sciences from January 1, 1964 to December 31, 2000.
  • Twenty-six patients had stage Idiseases, 8 stage II, 9 stage III, 1 stage IV and 13 recurrent and persistent diseases.
  • The uterus was involved in 41.2% patients with stage II-III diseases.
  • Combined modality was given to 52 cases and single-method treatment 5 cases.
  • The overall 5-year and 10-year survival rate for stage I-IV was 80.1% and 70.0% respectively.
  • The 5-year survival rate for stage I was 100%, stage II 55.2%, stage III 55.6%, stage IV 0% and recurrent and persistent diseases 72.7%.
  • In the group of stage I, 12 patients received adnexectomy and 14 patients underwent hysterectomy and adnex removal, there was no significant difference between the 5-year and 10-year survival rate (all 100%) (P < 0.05).
  • Of 23 patients in stage I group to whom only chemotherapy were given after operation, 19 cases received 3 or more courses and were well being without recurrence; four patients received only one course and one of them recurred 21 months after operation.
  • In the group of stage II and III cases the 5-year survival rate was 86.7% for those whose chemotherapy courses were > or = 4 and 25.0% for patients who received less than 4 courses of chemotherapy (P < 0.05).
  • CONCLUSIONS: The prognosis of ovarian dysgerminoma is closely related to disease stage and modality of treatment.
  • [MeSH-major] Dysgerminoma / therapy. Ovarian Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500404.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Low JJ, Perrin LC, Crandon AJ, Hacker NF: Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer; 2000 Jul 15;89(2):391-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Effective combination chemotherapy has improved the previously dismal prognosis for malignant ovarian germ cell tumors (MOGCT) dramatically.
  • In young patients, conservative surgery with adjuvant chemotherapy has made the preservation of fertility possible, even in patients with advanced disease.
  • METHODS: The current study is a retrospective review of 74 patients with MOGCT treated by conservative surgery, retaining the uterus and contralateral ovary to preserve ovarian function, with or without chemotherapy.
  • There were 56 International Federation of Gynecology and Obstetrics (FIGO) Stage I tumors (75.7%), 3 Stage II tumors, (4.1%), 11 Stage III tumors (14.9%), and 4 Stage IV tumors (5.4%).
  • Adjuvant chemotherapy was administered in 47 patients (63.5%).
  • Survival for patients with Stage I disease was 98.2% and that for patients with advanced disease stages was 94.4%.
  • During chemotherapy 61.7% of patients developed amenorrhea but 91.5% of these women resumed normal menstrual function on completion of chemotherapy.
  • Fourteen healthy live births were recorded in the chemotherapy group and there were no documented birth defects.
  • The majority of these patients who have received combination chemotherapy resume normal ovarian function and can expect a normal fertility rate and healthy offspring.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Cohort Studies. Cystectomy / methods. Female. Follow-Up Studies. Humans. Menstruation. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Omentum / surgery. Ovariectomy / methods. Reproduction. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10918171.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • The most common symptoms were abnormal vaginal bleeding (69.8%) and abdominal or pelvic pain (44.2%).Pelvic masses were found in 39.5% of the patients and enlarged corpus in 27.9% at physical examination, while pelvic masses were found in 67.4% of the 43 patients (29 cases) and thickening or abnormal endometrium in 23.3% (10 cases) during ultrasound examination.
  • Of 25 patients examined by CT/MRI, pelvic masses were found in 13 cases and enlarged uterus in 11 cases.
  • All 15 patients who underwent endometrial biopsies were proven to have endometrial carcinomas.
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma.
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3-year and 5-year survival rates of patients with early stage disease were better than those of the other patients (93.3%, 93.3% vs. 69.7%, 36.7%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


19. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ: Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol; 2002 Apr;186(4):651-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrauterine progesterone treatment of early endometrial cancer.
  • OBJECTIVE: Our purpose was to assess the feasibility of using a progesterone-containing intrauterine device (IUD) to treat presumed Federation Internationale Gynecologie et d'Obstetrique (FIGO) stage IA, grade 1 endometrioid cancer in women at high risk for perioperative complications.
  • STUDY DESIGN: Candidates were women with American Society of Anesthesiologists class III or IV grade 1 endometrioid cancer and no imaging evidence of myometrial invasion.
  • Subjects underwent hysteroscopy, curettage, and IUD placement, followed by endometrial biopsy every 3 months for 1 year.
  • Fourteen consented to participation; one was excluded at the time of IUD placement (grade 2 disease identified) and one was lost to follow-up.
  • CONCLUSION: Intrauterine progesterone appears to eradicate some cases of presumed stage IA, grade 1 endometrioid cancer in women at high risk for perioperative morbidity.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Progesterone / administration & dosage. Uterus / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Biopsy. Curettage. Drug Administration Routes. Female. Humans. Hysteroscopy. Intrauterine Devices, Medicated. Magnetic Resonance Imaging. Menopause. Middle Aged. Neoplasm Invasiveness. Ultrasonography

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11967486.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


20. Powell JL, Stinson JA, Connor GP, Shiro BS, Mattison M: Squamous cell carcinoma arising in a dermoid cyst of the ovary. Gynecol Oncol; 2003 Jun;89(3):526-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising in a dermoid cyst of the ovary.
  • BACKGROUND: Unlike ordinary germ cell tumors of the ovary, squamous cell carcinoma arising in a dermoid affects elderly persons.
  • CASE: The case of a 67-year-old woman with stage III squamous cell carcinoma arising in a dermoid cyst of the ovary and extending to the serosa and myometrium of the uterus, pelvic peritoneum, the serosa, and muscularis of the distal ileum and penetrating entirely through the wall of the sigmoid is presented.
  • She was treated with six cycles of Taxol and cisplatin chemotherapy at monthly intervals.
  • CONCLUSION: This is the fourth report of a prolonged disease-free survival of a patient with stage III squamous cell carcinoma arising in a dermoid cyst of the ovary.
  • This result is encouraging, but the best treatment for advanced cancer of this type has yet to be determined.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Dermoid Cyst / complications. Ovarian Neoplasms / etiology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Female. Humans. Neoplasm Staging. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12798723.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Sakuragi N, Hareyama H, Todo Y, Yamada H, Yamamoto R, Fujino T, Sagawa T, Fujimoto S: Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta Obstet Gynecol Scand; 2000 Apr;79(4):311-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma.
  • BACKGROUND: The serous adenocarcinoma (SA) and clear cell adenocarcinoma (CCA) of endometrium have been shown to be associated with high relapse rate and poor survival.
  • It is not clear whether prognostic significance of these specific cell types of tumor is independent of retroperitoneal lymph node metastasis and other histopathologic prognostic factors in endometrial carcinoma.
  • METHODS: We examined 240 consecutive patients with clinical stage I to stage III endometrial carcinoma who were treated prospectively with radical surgery and/or platinum-based chemotherapy.
  • Of 216 clinically staged stage I or II disease, seven of 12 cases of SA/CCA had extrauterine disease.
  • A multivariate Cox regression analysis revealed that cell type, grade, LVSI, and paraaortic node metastasis (PANM) were independent prognosticators.
  • CONCLUSIONS: Prognosis of patients with endometrial carcinoma depends on cell type, grade, LVSI, and PANM.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10746848.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] DENMARK
  •  go-up   go-down


22. Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, Keeney GL: The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol; 2010 Mar;116(3):419-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of multi-modal therapy on survival for uterine carcinosarcomas.
  • OBJECTIVES: To investigate treatment outcomes of patients with carcinosarcoma of the uterus and to identify parameters predictive of survival.
  • Secondary objectives included (a) the assessment of treatment failures as a function of histologic subtypes and (b) the impact of the new FIGO staging classification system.
  • METHODS: This is a retrospective outcomes analysis of 121 patients diagnosed with primary carcinosarcoma of the uterus.
  • Clinical, surgical and pathological data were reviewed and patients were classified according to the new 2009 FIGO staging system for endometrial carcinoma.
  • RESULTS: In the multivariate analyses for disease-specific survival (DSS) and disease-free survival (DFS), the only independent factors were FIGO stage, adjuvant chemotherapy after surgery and the presence of clear cell histology in the tumor.
  • The 5-year DSS for stages I-II, III and IV was 59%, 22% and 9%, respectively.
  • The administration of platin-based chemotherapy provided a significant benefit with regard to both DFS (OR=0.28; p=0.001) and DSS (OR=0.35; p=0.01).
  • CONCLUSIONS: This highly aggressive uterine malignancy warrants comprehensive surgical staging to assess tumor dissemination followed by systemic therapy in patients with both early and advanced stage disease.
  • [MeSH-major] Carcinosarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19896181.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol; 2006 Aug;108(2):361-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
  • OBJECTIVE: To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy.
  • METHODS: Patients with stage II-IV low-grade serous carcinoma of the ovary from 1978 to 2003 were identified using existing databases.
  • ; 90% had stage III disease.
  • Preoperative serum CA 125 was elevated in 86% of patients.
  • The most common sites of extraovarian disease were omentum, fallopian tubes, pelvic peritoneum, and uterus.
  • Response rate to platinum-based chemotherapy in 10 evaluable patients (15% of patients with gross residual disease) was 80%, and 42 patients underwent second-look surgery: microscopically negative findings, 2 (5%); microscopically positive disease, 13 (33%); macroscopically positive disease, 24 (62%); and insufficient information, 3 (7%).
  • Median progression-free survival and overall survival times were 19.5 and 81.8 months.
  • Persistent disease after primary chemotherapy was the only factor associated with shorter overall survival time (hazard ratio 3.46, 95% confidence interval 2.00-5.97, P<.001).
  • CONCLUSION: Metastatic low-grade serous carcinoma of the ovary is characterized by young age at diagnosis and prolonged overall survival.
  • [MeSH-major] Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Texas / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880307.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ: Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):786-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
  • PURPOSE: To determine the survival outcomes, prognostic factors, and patterns of failure in patients with malignant mixed Müllerian tumor (MMMT) of the uterus.
  • METHODS AND MATERIALS: Between 1954 and 1998, 300 patients with clinical Stage I-III MMMT of the uterus were treated with curative intent at The University of Texas M. D.
  • Anderson Cancer Center.
  • Their hospital records were reviewed to obtain patient and tumor characteristics; details of surgery, radiotherapy (RT), and chemotherapy; and long-term outcome.
  • Forty-eight patients received adjuvant chemotherapy.
  • Women who were postmenopausal or had a history of prior pelvic RT, pain at presentation, clinical Stage II-III disease, uterine enlargement (>/=12 weeks), or an abnormal Papanicolaou smear finding had a significantly poorer prognosis than the other patients in the series.
  • Of the 273 patients who underwent surgery, those who had positive abdominal washings, uterine length >10 cm, or extrauterine spread of disease to the cervix, adnexa, or peritoneum had a significantly worse prognosis than the other patients.
  • Factors found on multivariate analysis to have an independent adverse influence on cause-specific survival included postmenopausal status (p = 0.0007, relative risk [RR] 3.3), uterine length >10 cm (p = 0.0001, RR 2.2), cervical involvement (p = 0.002, RR 1.8), and peritoneal involvement (p = 0.0001, RR 4.3).
  • However, patients treated with pelvic RT had a longer mean time to any distant relapse (17.3 vs. 7.0 months, p = 0.001) than patients treated with surgery alone.
  • The use of adjuvant chemotherapy did not correlate with the survival rate or rate of distant metastasis.
  • As more effective systemic chemotherapy is developed to control microscopic distant disease, the role of RT in controlling locoregional disease in the pelvis and abdomen may become more important.
  • Future research should consider programs that integrate surgery, RT, and chemotherapy to maximize the probability of cure.
  • [MeSH-major] Mixed Tumor, Malignant / mortality. Mixed Tumor, Mullerian / mortality. Uterine Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Postmenopause. Postoperative Complications. Prognosis. Radiation Injuries / pathology. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967435.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hu Y, Feng FY, Zhang P, Zhou LQ, Zhang WH, Wang QL: [Primary non-Hodgkin lymphoma in the female genital system: a report of 28 cases]. Zhonghua Zhong Liu Za Zhi; 2003 Sep;25(5):486-9
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinical characteristics, results of treatment, and prognostic factors of patients diagnosed as having primary female genital system lymphoma (PFGSL).
  • METHODS: Twenty-eight cases of PFGSL were retrospectively surveyed and the clinical data of the patients were analyzed by statistic software package of SPSS10.0 for relation between clinical stage, grade, pathologic feature, treatment and prognosis.
  • It mainly involved cervix uterus, ovary and vulva.
  • The disease had a broad range of pathologic type and 20 patients were diagnosed as suffering from B-cell by immunophenotyping, 4 patients were diagnosed as T-cell and 4 patients lesions were indefinite.
  • The Ann Arbor stage included: Stage I(E)-12 pts (42.86%), Stage II(E)-3 pts (10.7%), Stage III(E)-1 pts (3.6%) and Stage IV-12 pts (42.86%).
  • Most patients were given comprehensive treatment without any mode showing significant advantage over the others in survival (P = 0.2554), The involved organs, Ann Arbor stage, IWF and also IPI were significant prognostic factors for survival, CONCLUSION: The management of PFGSL should be based on comprehensive treatment including chemotherapy as the chief means.
  • The significant prognostic factors of survival is Ann Arbor stage, IPI, IWF and the kind of involved organs.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14575576.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH: Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol; 2008 Sep;110(3):345-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes.
  • OBJECTIVE: Younger patients with invasive epithelial ovarian cancer (EOC) frequently want to preserve their fertility, but the role of fertility-sparing surgery in EOC has not been well defined.
  • METHODS: Records of 62 patients with invasive EOC who underwent fertility-sparing surgery, defined as the preservation of ovarian tissue in one or both adnexa and the uterus, between May 1990 and October 2006, were retrospectively reviewed.
  • RESULTS: Of the 62 EOCs, 36 were stage IA, 2 were stage IB, 21 were stage IC, and 1 each was stage IIB, IIIA, and IIIC; 48 were grade I, 5 were grade II, and 9 were grade III.
  • Forty-eight patients received platinum-based adjuvant chemotherapy (mean 4.6 cycles, range 1-9 cycles).
  • Patients with stage >IC (p=0.0014) or grade III (p=0.0002) tumors had significantly poorer survival.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Disease-Free Survival. Female. Gynecologic Surgical Procedures / adverse effects. Gynecologic Surgical Procedures / methods. Humans. Neoplasm Invasiveness. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2009 Mar;112(3):673-4; author reply 674 [18986689.001]
  • (PMID = 18586310.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Dem A, Kasse AA, Diop M, Cisse B, Toure P: [Epidemiological factors, treatment and prognosis of uterine sarcomas: 14 cases at the Cancer Institute of Dakar]. Dakar Med; 2000;45(1):85-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological factors, treatment and prognosis of uterine sarcomas: 14 cases at the Cancer Institute of Dakar].
  • [Transliterated title] Etude des facteurs épidémiologiques, du traitement et du prognostic des sarcomes de l'utérus: à propos de 14 cas colligés à l'Institut du Cancer de Dakar.
  • The study of uterus sarcoma took in interest because these tumors were unrecognized and sat nowadays many questions.
  • The purpose of this study is to review the epidemiological factors, the problems of treatment and prognostic of uterus sarcoma.
  • It's a retrospective study of 14 sarcomas of uterus reported from 1959 to 1997.
  • The clinical investigation found according the FIGO staging: 6 stage I (42.6%), 4 stage II (28.4%), 1 stage III (7.1%) and 3 stage IV (21.4%).
  • Surgery was the principal treatment: it was alone on 3 cases (24.9%), associated with chemotherapy on 8 cases (66.8%) and one patient had an association surgery, chemotherapy and radiotherapy.
  • The global survival was 21.4% at 2 years and all the patients were dead at 5 years and it seemed that it would be better when the patients were treated by radical surgery associated with chemotherapy and radiotherapy.
  • [MeSH-major] Sarcoma / epidemiology. Sarcoma / therapy. Uterine Neoplasms / epidemiology. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Age Distribution. Aged. Biopsy. Cancer Care Facilities. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Postmenopause. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Senegal / epidemiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666799.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Senegal
  •  go-up   go-down


28. Kreĭnina IuM, Titova VA, Shipilova AN, Povarova EV, Shevchenko LN: [Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer]. Vopr Onkol; 2006;52(1):83-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer].
  • Clinical data on the management of squamous-cell cervical carcinoma stage II-III FIGO are presented.
  • At stage I, treatment included neoadjuvant polychemotherapy (NACT)--cisplatin 100 mg/m2, carboplatin 450 mg/m2 in conjunction with 5-FU 250 mg/m2 or paclitaxel 135 mg/m2.
  • According to protocol, two identical courses of NACT were given, at 21-28 day interval, followed by extended extirpation of the uterus (Wertheim).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Hysterectomy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Outcome


29. Rosen AC, Ausch C, Klein M, Graf AH, Metzenbauer M, Philipp K, Reiner A: p53 expression in fallopian tube carcinomas. Cancer Lett; 2000 Aug 1;156(1):1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-three women treated for primary carcinoma of the fallopian tube (PFTC) from 1980-1995 were retrospectively analyzed to study the impact of p53 expression on survival in primary carcinoma of the fallopian tube.
  • Twenty-four (38%) patients were FIGO stage I, 11 (18%) stage II, 19 (30%) stage III and nine (14%) stage IV.
  • In 56 (89%) women, surgery involved removal of the uterus, the adnexa, and/or the omentum or lymph nodes.
  • Adjuvant therapy consisted of either chemotherapy (n: 31; 49%) or irradiation (n: 21; 33%).
  • For stages I+II and III+IV the 5-year survival rate was 59 and 19%, respectively (P<0.00001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840153.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


30. Terada T: KIT-positive primary small cell carcinoma of the endometrium: a case report with immunohistochemical and molecular genetic analysis of KIT and PDGFRA genes. Arch Gynecol Obstet; 2010 Oct;282(4):413-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT-positive primary small cell carcinoma of the endometrium: a case report with immunohistochemical and molecular genetic analysis of KIT and PDGFRA genes.
  • BACKGROUND: Primary small cell carcinoma of the endometrium is very rare, and there have been no reports on KIT and PDGFRA in endometrial small cell carcinoma.
  • Endometrial cytology and biopsy revealed small cell carcinoma.
  • Scrutiny of the body showed stage III endometrial carcinoma with metastases.
  • The patient received chemotherapy and radiation, but showed a downhill course, and died of carcinomatosis 6 months after the initial presentation.
  • CONCLUSION: The present case is the first reported case of primary small cell carcinoma of the endometrium with an examination of KIT and PDGFRA expressions and KIT and PDFGRA gene mutations.
  • [MeSH-major] Carcinoma, Small Cell / genetics. Endometrial Neoplasms / genetics. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Aged, 80 and over. Biopsy. DNA Mutational Analysis. Drug Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. Polymerase Chain Reaction. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035340.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


31. Mimatsu K, Oida T, Kuboi Y, Kawasaki A, Kanou H, Kaneda H, Amano S: A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy. Int J Clin Oncol; 2004 Jun;9(3):193-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy.
  • Conventional gastrojejunostomy has been employed for unresectable advanced gastric cancer with pyloric stenosis; however, it is often not fully effective.
  • We report a patient with unresectable gastric cancer who was effectively treated with an anticancer drug, S-1, after receiving an improved gastrojejunostomy.
  • Upper gastrointestinal endoscopy showed a Borrmann III tumor in the antrum of the stomach, and gastric roentgenography showed pyloric stenosis.
  • Preoperative findings were T3N2H0P0, stage III b.
  • A curative operation was impossible for the advanced gastric cancer.
  • She started treatment with 80 mg/day of S-1, given orally, for 28 days, followed by 14 days' rest, as 1 course.
  • During 16 courses of the treatment, she maintained a performance status of 0 to 1 and maintained quality of life.
  • However, she died because of pelvic dissemination and genital bleeding (caused by tumor invasion into the uterus) 2 years and 4 months after the surgery.
  • This case suggested that the improved gastrojejunostomy was a useful method for treating unresectable gastric cancer, allowing the possibility of oral intake, and the use of S-1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Anastomosis, Surgical. Drug Combinations. Female. Humans. Jejunum / surgery. Middle Aged. Palliative Care. Stomach / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15221605.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down






Advertisement